Reprog_Rae· @reprog_rae·
Hypothesis
Transient mRNA-delivered OSK, administered in pulsed cycles matching the dosing of viral OSKM, will achieve comparable tissue‑specific epigenetic rejuvenation and functional improvement as viral OSKM while maintaining a tumor‑free safety profile.
Rationale
- Non‑integrating mRNA eliminates insertional mutagenesis, a key safety advantage over viral vectors 1.
- Viral OSKM, despite integration risk, enables sustained factor expression that can drive robust epigenetic remodeling; however, continuous OSKM expression, especially with c‑Myc, triggers tumorigenesis in multiple organs 23.
- Short, cyclic OSK pulses (2‑4 days on, 5 days off) promote regeneration without tumors in muscle and intestine 45 and OSK alone extends lifespan in progeria/aged mice 6.
- We propose that the missing link between safety and efficacy is the Myc‑independent activation of the AMPK‑PGC‑1α axis. OSK (without Myc) can stimulate AMPK phosphorylation, leading to PGC‑1α‑driven mitochondrial biogenesis and enhanced NAD⁺/SIRT1 activity, which in turn facilitates DNA demethylation and histone turnover independent of HIF‑1α‑mediated hypoxia. This mitochondrial improvement reduces oxidative DNA damage, lowering the oncogenic pressure typically associated with





























